Skip to main content

Startup Biomarker Instrument Firm Avantra Biosciences Raises $7M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Newly formed Avantra Biosciences has raised $7 million, it disclosed in a document filed with the US Securities and Exchange Commission on Monday.

The Woburn, Mass.-based firm said the funds raised were in the form of equity and will not be used for a merger, acquisition, exchange offer, or other business combination transaction. It did not specify how the money will be used, but last month GenomeWeb Daily News' sister publication ProteoMonitor reported that Avantra plans to launch the Avantra Biomarker Workstation and accompanying assays early next year after closing of the Series B round.

Avantra was launched at the end of last year by Courtagen Capital Group from the ashes of Decision Biomarkers. Courtagen bought the assets of Decision Biomarkers after the protein biomarker technology firm shuttered its business and filed for Chapter 7 bankruptcy.

The Biomarker Workstation was developed by Decision Biomarkers and is used for biomarker detection.

In its SEC filing, Avantra lists Brian McKernan as its CEO and Brendan McKernan as its president.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.